27th Apr 2010 15:16
SkyePharma PLC - Annual Information Update
In accordance with the requirements of Prospectus Rule 5.2, the following information and documents were published, or made available to the public, over the 12 months from 24 April 2009 to 26 April 2010 (inclusive) in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.
This annual information update is required by, and is being made pursuant to Prospectus Article 10 of the Prospectus Directive as implemented in the UK by Prospectus Rule 5.2.3G made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither SkyePharma PLC ('the Company'), nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained herein or referred to below. The information contained below or referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on in such respect by any person.
1. Announcements via RNS
The following UK regulatory announcements have been made via RNS a Regulatory Information Service and can be obtained from the London Stock Exchange website at www.londonstockexchange.com or the Company's website at www.skyepharma.com
Date |
Announcement |
24/04/09 |
Annual Information Update |
01/05/09 |
Share Purchase Plan |
11/05/09 |
Conversion of Bonds |
15/05/09 |
Interim Management Statement |
15/05/09 |
Board Appointment |
15/05/09 |
AGM Results |
22/05/09 |
Flutiform NDA Accepted for Review |
27/05/09 |
Replacement: Conversion of £50,000 6% 2024 Bonds |
28/05/09 |
Holding(s) in Company |
29/05/09 |
Total Voting Rights |
29/05/09 |
Share Purchase Plan |
03/06/09 |
Director/PDMR Holding |
04/09/09 |
Holding(s) in Company |
05/06/09 |
Holding(s) in Company |
05/06/09 |
Holding(s) in Company |
05/06/09 |
Holding(s) in Company |
09/06/09 |
Research Update |
09/06/09 |
Holding(s) in Company |
10/06/09 |
Holding(s) in Company |
11/06/09 |
Holding(s) in Company |
17/06/09 |
Holding(s) in Company |
17/06/09 |
Holding(s) in Company |
22/06/09 |
Conversion of Bonds |
22/06/09 |
Holding(s) in Company |
23/06/09 |
Holding(s) in Company |
24/06/09 |
Holding(s) in Company |
26/06/09 |
Holding(s) in Company |
30/06/09 |
Total Voting Rights |
30/06/09 |
Share Purchase Plan |
01/07/09 |
Director Declaration |
09/07/09 |
Holding(s) in Company |
10/07/09 |
Holding(s) in Company |
14/07/09 |
Holding(s) in Company |
17/07/09 |
Re Agreement |
20/07/09 |
Holding(s) in Company |
24/07/09 |
Holding(s) in Company |
24/07/09 |
Holding(s) in Company |
03/08/09 |
Share Purchase Plan |
21/08/09 |
Half Yearly Report |
01/09/09 |
Research Update |
01/09/09 |
Share Purchase Plan |
08/09/09 |
Holding(s) in Company |
01/10/09 |
Share Purchase Plan |
02/11/09 |
SkyePharma Announces Successful Completion of Flutiform™ EU Clinical Trial Programme |
03/11/09 |
Share Purchase Plan |
12/11/09 |
Interim Management Statement |
18/11/09 |
Board Change |
01/12/09 |
Share Purchase Plan |
22/12/09 |
Share Purchase Plan |
04/01/10 |
Directorate Change |
05/01/10 |
Holding(s) in Company |
06/01/10 |
Holding(s) in Company |
12/01/10 |
Holding(s) in Company |
13/01/10 |
Holding(s) in Company |
18/01/10 |
Holding(s) in Company |
19/01/10 |
Holding(s) in Company |
20/01/10 |
Holding(s) in Company |
21/01/10 |
Regulatory Update |
22/01/10 |
Holding(s) in Company |
01/02/10 |
Share Purchase Plan |
05/02/10 |
Flutiform US NDA update |
01/03/10 |
Share Purchase Plan |
25/03/10 |
Preliminary Results 2009 |
08/04/10 |
Share Purchase Plan |
14/04/10 |
Annual Report and Accounts |
2. Documents filed at Companies House
All of the documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated. Copies of the documents filed with the Registrar of Companies can be obtained from Companies House (www.companieshouse.gov.uk)
Date of Filing |
Brief Description of document(s) filed |
|
18/05/2009 |
RES01 |
AGM Special Resolutions |
18/05/2009 |
MEM/ARTS |
Articles of Association |
18/05/2009 |
AA |
Annual Report and Accounts |
18/05/2009 |
288b |
Resignation of a Director or Secretary |
18/05/2009 |
288a |
Appointment of a Director or Secretary |
18/05/2009 |
88(2) |
Return of Allotment of Shares |
18/05/2009 |
88(3) |
Particulars of a Contract Relating to Shares |
23/07/2009 |
88(2) |
Return of Allotment of Shares |
23/07/2009 |
88(3) |
Particulars of a Contract Relating to Shares |
01/10/2009 |
CH01 |
Change of director's details |
01/10/2009 |
CH01 |
Change of director's details |
01/10/2009 |
CH01 |
Change of director's details |
01/10/2009 |
CH01 |
Change of director's details |
01/10/2009 |
CH03 |
Change of secretary's details |
01/10/2009 |
AD02 |
Notification of single alternative inspection location |
01/10/2009 |
AD03 |
Change of location of the company records to the SAIL |
01/10/2009 |
CH01 |
Change of director's details |
04/01/2010 |
TM01 |
Termination of appointment of director |
21/01/2010 |
AR01 |
Annual Return |
3. Documents published or sent to Shareholders or filed with the UK Listing Authority viewing facility at:
Financial Services Authority
The North Colonnade
Canary Wharf
London
E14 5HS
Date |
Document |
14/04/10 |
Annual Report and Accounts 2009 |
14/04/10 |
Notice of General Meeting 2010 |
14/04/10 |
Form of Proxy |
14/04/10 |
Proposed New Articles of Association |
14/04/10 |
Amended Current Articles of Association |
14/04/10 |
Amended Memorandum of Association |
Copies of the above reports can be obtained from the Company Secretary at:
105 Piccadilly
London
W1J 7NJ
All of the above information was up-to-date at the time of publication but it is acknowledged that such disclosures may, at any time, be out of date due to changing circumstances.
Name of contact and telephone number for queries:
John Murphy
Company Secretary
SkyePharma PLC
Tel: 020 7491 1777
Related Shares:
SKP.L